Publication:


abstract

Nitrosatable drugs, such as secondary or tertiary amines and amides, form N-nitroso compounds in the presence of nitrite. Various N-nitroso compounds have been associated with neural tube Defects in animal models. Using data from the National Birth Defects Prevention Study, the authors examined nitrosatable drug exposure 1 month before and 1 month after conception in 1,223 case mothers with neural tube defect-affected pregnancies and 6,807 control mothers who delivered babies without major congenital anomalies from 1997 to 2005. Nitrite intakes were estimated from mothers' responses to a food frequency questionnaire. After adjustment for maternal race/ethnicity, educational level, and folic acid supplementation, case women were more likely than were control women to have taken tertiary amines (odds ratio = 1.60, 95% confidence interval (CI): 1.31, 1.95). This association was strongest with anencephalic births (odds ratio = 1.96, 95% CI: 1.40, 2.73); odds ratios associated with tertiary amines from the lowest tertile of nitrite intake to the highest tertile were 1.16 (95% CI: 0.59, 2.29), 2.19 (95% CI: 1.25, 3.86), and 2.51 (95% CI: 1.45, 4.37), respectively. Odds ratios for anencephaly with nitrosatable drug exposure were reduced among women who also took daily vitamin supplements that contained vitamin C. Prenatal exposure to nitrosatable drugs may increase the risk of neural tube defects, especially in conjunction with a mother's higher dietary intake of nitrites, but vitamin C might modulate this association.

Related Articles
Dietary nitrites and nitrates, nitrosatable drugs, and neural tube defects.
Epidemiology. 2004
Dietary nitrites and nitrates, nitrosatable drugs, and neural tube defects.
Brender JD, Olive JM, Felkner M, Suarez L, Marckwardt W, Hendricks KA. Epidemiology. 2004 May; 15(3):330-6.
Prevalence and patterns of nitrosatable drug use among U.S. women during early pregnancy.
Birth Defects Res A Clin Mol T...
Prevalence and patterns of nitrosatable drug use among U.S. women during early pregnancy.
Brender JD, Kelley KE, Werler MM, Langlois PH, Suarez L, Canfield MA, National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2011 Apr; 91(4):258-64. Epub 2011 Apr 6.
Maternal prenatal exposure to nitrosatable drugs and childhood brain tumours.
Int J Epidemiol. 2003
Maternal prenatal exposure to nitrosatable drugs and childhood brain tumours.
McKean-Cowdin R, Pogoda JM, Lijinsky W, Holly EA, Mueller BA, Preston-Martin S. Int J Epidemiol. 2003 Apr; 32(2):211-7.
Review Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis.
J Obstet Gynaecol Can. 2006
Review Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis.
Goh YI, Bollano E, Einarson TR, Koren G. J Obstet Gynaecol Can. 2006 Aug; 28(8):680-9.
Review The use of folic acid for the prevention of neural tube defects and other congenital anomalies.
J Obstet Gynaecol Can. 2003
Review The use of folic acid for the prevention of neural tube defects and other congenital anomalies.
Wilson RD, Davies G, Désilets V, Reid GJ, Summers A, Wyatt P, Young D, Genetics Committee and Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. J Obstet Gynaecol Can. 2003 Nov; 25(11):959-73.